{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:11:58Z","timestamp":1783609918132,"version":"3.55.0"},"reference-count":53,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To identify predictive gene-expression signatures for immune-related adverse events (irAEs) in patients with melanoma treated with anti-PD-1 inhibitors, in the adjuvant therapy (AT) and first-line therapy (FLT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study analyzed baseline whole-blood gene expression profile from 161 patients with resected stage III or unresectable stage III-IV melanoma treated with anti-PD-1 inhibitors. RNA was extracted from baseline peripheral blood samples and profiled using the NanoString nCounter PanCancer IO 360 panel. Gene-expression signatures were identified and validated using cross-validated sparse partial least squares modeling and principal component analysis, then correlated with toxicity occurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 223 and 186 irAEs were observed in the AT and FLT groups, respectively, including arthralgia, colitis, and headache. Distinct gene-expression signatures significantly predicted toxicity occurrence, with variation across therapy settings. Arthralgia was predicted by immune-related and apoptotic gene signatures (eg, SMAD5, FASLG in FLT; ICOS, TGFB2 in AT), while colitis was linked to inflammatory and adhesion-related pathways. In the AT group, headache was associated with genes involved in interferon and adhesion signaling. Across both cohorts, specific signatures predicted overall irAE risk and timing. No events were observed in patients with low-risk signatures over the follow-up period. In the FLT cohort, arthralgia and cutaneous toxicities were positively associated with ORR, while arthralgia, asthenia, colitis, fatigue, and skin-related toxicities correlated with improved disease control rate. No significant association between irAEs and relapse risk was observed in the adjuvant cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Whole-blood gene-expression profiling enables early identification of patients at high risk for irAEs during anti-PD-1 therapy. These predictive biomarkers may guide personalized toxicity monitoring in melanoma treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-011315","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T02:53:31Z","timestamp":1752548011000},"page":"e011315","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Gene-expression signature predicts autoimmune toxicity in metastatic melanoma"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5313","authenticated-orcid":false,"given":"Domenico","family":"Mallardo","sequence":"first","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fordellone","sequence":"additional","affiliation":[{"name":"Salute Mentale e Fisica e Medicina Preventiva, University of Campania Luigi Vanvitelli, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bailey","sequence":"additional","affiliation":[{"name":"Research and Development, NanoString Technologies Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"White","sequence":"additional","affiliation":[{"name":"Research and Development, NanoString Technologies Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Festino","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Vanella","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trojaniello","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Vitale","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-0808","authenticated-orcid":false,"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-2532","authenticated-orcid":false,"given":"Mariaelena","family":"Capone","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Costa","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6737-7736","authenticated-orcid":false,"given":"Maria","family":"Ingenito","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sparano","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Arianna","family":"Facchini","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-1579","authenticated-orcid":false,"given":"Ernesta","family":"Cavalcanti","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Istituto Nazionale Tumori \u2013 IRCCS \u2013 Fondazione 'G. Pascale', Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"De Filippi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carac\u00f2","sequence":"additional","affiliation":[{"name":"Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori \u2013 IRCCS \u2013 Fondazione 'G. Pascale', Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cesano","sequence":"additional","affiliation":[{"name":"ESSA Pharma, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Warren","sequence":"additional","affiliation":[{"name":"ESSA Pharma, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Chiodini","sequence":"additional","affiliation":[{"name":"Salute Mentale e Fisica e Medicina Preventiva, University of Campania Luigi Vanvitelli, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-6053","authenticated-orcid":false,"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[{"name":"Scientifc Directorate, Istituto Nazionale Tumori \u2013 IRCCS \u2013 Fondazione 'G. Pascale', Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025100305564512000_13.7.e011315.1","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J Immunol Res"},{"key":"2025100305564512000_13.7.e011315.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2025100305564512000_13.7.e011315.3","unstructured":"NIH National Library of Medicine . A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03), Available: https:\/\/clinicaltrials.gov\/study\/NCT00730639"},{"key":"2025100305564512000_13.7.e011315.4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100305564512000_13.7.e011315.5","unstructured":"NIH National Library of Medicine . Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990\/MK-3475-001\/KEYNOTE-001) (KEYNOTE-001), Available: https:\/\/clinicaltrials.gov\/study\/NCT01295827"},{"key":"2025100305564512000_13.7.e011315.6","unstructured":"NIH National Library of Medicine . Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006\/KEYNOTE-006), Available: https:\/\/clinicaltrials.gov\/study\/NCT01866319"},{"key":"2025100305564512000_13.7.e011315.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.010"},{"key":"2025100305564512000_13.7.e011315.8","unstructured":"NIH National Library of Medicine . Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb\/c or Stage IV Melanoma (CheckMate 238), Available: https:\/\/clinicaltrials.gov\/study\/NCT02388906"},{"key":"2025100305564512000_13.7.e011315.9","unstructured":"NIH National Library of Medicine . Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054\/1325-MG\/KEYNOTE-054), Available: https:\/\/clinicaltrials.gov\/study\/NCT02362594"},{"key":"2025100305564512000_13.7.e011315.10","unstructured":"NIH National Library of Medicine . Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB\/C Melanoma (CheckMate76K), Available: https:\/\/clinicaltrials.gov\/study\/NCT04099251"},{"key":"2025100305564512000_13.7.e011315.11","unstructured":"NIH National Library of Medicine . Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716\/KEYNOTE-716), Available: https:\/\/clinicaltrials.gov\/study\/NCT03553836"},{"key":"2025100305564512000_13.7.e011315.12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164125","article-title":"Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field","volume":"15","author":"Eljilany","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025100305564512000_13.7.e011315.13","unstructured":"NIH National Library of Medicine . Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067), Available: https:\/\/clinicaltrials.gov\/study\/NCT01844505"},{"key":"2025100305564512000_13.7.e011315.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2407417"},{"key":"2025100305564512000_13.7.e011315.15","unstructured":"NIH National Library of Medicine . Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN), Available: https:\/\/clinicaltrials.gov\/study\/NCT02437279"},{"key":"2025100305564512000_13.7.e011315.16","unstructured":"NIH National Library of Medicine . Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo), Available: https:\/\/clinicaltrials.gov\/study\/NCT02977052"},{"key":"2025100305564512000_13.7.e011315.17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"2025100305564512000_13.7.e011315.18","unstructured":"NIH National Library of Medicine . A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma, Available: https:\/\/clinicaltrials.gov\/study\/NCT02714218"},{"key":"2025100305564512000_13.7.e011315.19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100305564512000_13.7.e011315.20","unstructured":"NIH National Library of Medicine . A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047), Available: https:\/\/clinicaltrials.gov\/study\/NCT03470922"},{"key":"2025100305564512000_13.7.e011315.21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"key":"2025100305564512000_13.7.e011315.22","unstructured":"NIH National Library of Medicine . An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread, Available: https:\/\/clinicaltrials.gov\/study\/NCT03459222"},{"key":"2025100305564512000_13.7.e011315.23","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2024.42.16_suppl.9504","article-title":"Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048","volume":"42","author":"Ascierto","year":"2024","journal-title":"JCO"},{"key":"2025100305564512000_13.7.e011315.24","unstructured":"NIH National Library of Medicine . A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i), Available: https:\/\/clinicaltrials.gov\/study\/NCT02967692"},{"key":"2025100305564512000_13.7.e011315.25","unstructured":"NIH National Library of Medicine . A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma, Available: https:\/\/clinicaltrials.gov\/study\/NCT02908672"},{"key":"2025100305564512000_13.7.e011315.26","unstructured":"NIH National Library of Medicine . A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022\/KEYNOTE-022), Available: https:\/\/clinicaltrials.gov\/study\/NCT02130466"},{"key":"2025100305564512000_13.7.e011315.27","first-page":"4019","article-title":"Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients","volume":"30","author":"Gunturu","year":"2022","journal-title":"Support Care Cancer"},{"key":"2025100305564512000_13.7.e011315.28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"2025100305564512000_13.7.e011315.29","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-24-0900","article-title":"Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma","volume":"30","author":"Monson","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025100305564512000_13.7.e011315.30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response","volume":"46","author":"Curry","year":"2019","journal-title":"J Cutan Pathol"},{"key":"2025100305564512000_13.7.e011315.31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","article-title":"Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100305564512000_13.7.e011315.32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12967-023-04419-6","article-title":"CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy","volume":"21","author":"Mallardo","year":"2023","journal-title":"J Transl Med"},{"key":"2025100305564512000_13.7.e011315.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005132","article-title":"Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis","volume":"10","author":"Mallardo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100305564512000_13.7.e011315.34","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03643-w","article-title":"Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization","volume":"20","author":"Mallardo","year":"2022","journal-title":"J Transl Med"},{"key":"2025100305564512000_13.7.e011315.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.007"},{"key":"2025100305564512000_13.7.e011315.36","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.036236","article-title":"Immune regulation of metastasis: mechanistic insights and therapeutic opportunities","volume":"11","author":"Blomberg","year":"2018","journal-title":"Dis Model Mech"},{"key":"2025100305564512000_13.7.e011315.37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212439","article-title":"ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma","volume":"25","author":"Mallardo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025100305564512000_13.7.e011315.38","first-page":"1169","article-title":"RB1 oncosuppressor gene over-expression inhibits tumor progression and induces melanogenesis in metastatic melanoma cells","volume":"13","author":"Valente","year":"1996","journal-title":"Oncogene"},{"key":"2025100305564512000_13.7.e011315.39","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI94295","article-title":"SMAD signaling promotes melanoma metastasis independently of phenotype switching","volume":"129","author":"Tuncer","year":"2019","journal-title":"J Clin Invest"},{"key":"2025100305564512000_13.7.e011315.40","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0289"},{"key":"2025100305564512000_13.7.e011315.41","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.135"},{"key":"2025100305564512000_13.7.e011315.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30338-4","article-title":"CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells","volume":"8","author":"Wicklein","year":"2018","journal-title":"Sci Rep"},{"key":"2025100305564512000_13.7.e011315.43","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199906000-00008"},{"key":"2025100305564512000_13.7.e011315.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139285","article-title":"Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS ONE"},{"key":"2025100305564512000_13.7.e011315.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.06.004"},{"key":"2025100305564512000_13.7.e011315.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.03.036"},{"key":"2025100305564512000_13.7.e011315.47","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1297910","article-title":"Canonical Wnt and TGF-\u03b2\/BMP signaling enhance melanocyte regeneration but suppress invasiveness, migration, and proliferation of melanoma cells","volume":"11","author":"Katkat","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2025100305564512000_13.7.e011315.48","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108344","article-title":"Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma","volume":"101","author":"Jiang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2025100305564512000_13.7.e011315.49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4149\/neo_2024_240116N24","article-title":"Calreticulin regulates the expression of MMP14 and ADAR1 through EIF2AK2 signaling to promote the proliferation and progression of malignant melanoma cells","volume":"71","author":"Liang","year":"2024","journal-title":"Neoplasma"},{"key":"2025100305564512000_13.7.e011315.50","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28928","article-title":"Distinct roles of CD244 expression in cancer diagnosis and prognosis: A pan-cancer analysis","volume":"10","author":"Deng","year":"2024","journal-title":"Heliyon"},{"key":"2025100305564512000_13.7.e011315.51","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature New Biol"},{"key":"2025100305564512000_13.7.e011315.52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol"},{"key":"2025100305564512000_13.7.e011315.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:57:01Z","timestamp":1759496221000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/jitc-2024-011315"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011315","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}